The study shows that the medication Ozempic reduces the risk of heart attack, stroke
and death with more than one competitor from the American Eli Lilly.
Ozempic reduces these risks by 23 percent compared to competitor Lilly's dulaglutide, states Novo Nordisk with reference to the first direct comparative study in real life.
